Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 23Neoplasm Metastasis 11Carcinoma, Non-Small-Cell Lung 6Prostatic Neoplasms 5Neoplasms 3Brain Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma, Ewing 2Pancreatic Neoplasms 2Glioblastoma 2Urogenital Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Neoplasms, Squamous Cell 1Metastatic Castration-Resistant Prostate Cancer 1Melanoma 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma 1Hormone Receptor Positive Breast Cancer 1Head and Neck Neoplasms 1Glioma 1Ependymoma 1

Interventions

Nivolumab 11Ipilimumab 6linrodostat 4relatlimab 3Pemetrexed 2tislelizumab 1regorafenib 1ralimetinib 1p38 Mitogen-Activated Protein Kinases 1mirdametinib 1gedatolisib 1figitumumab 1efatutazone 1abemaciclib 1Vorinostat 1Tetanus Toxoid 1Tamoxifen 1Sunitinib 1Ranitidine 1Midazolam 1LY2603618 1LY2584702 1Irinotecan 1Gemcitabine 1Fulvestrant 1Dasatinib 1Cyclophosphamide 1Crizotinib 1Cetuximab 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced Cancer × abemaciclib × Clear all
NCT01394016 2024-09-19

A Phase 1 Study of LY2835219 In Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
225 enrolled 31 charts

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡